covid vaccine and is working on improving the yield of the second dose and the management is also focused on the manufacture of Sputik light as well, its MD and CEO, Srinivas Sadu said as part of the CEO Track at Annual Global Investor Conference (AGIC) CY21 hosted by Motilal Oswal.
The brokerage in a note said that Gland Pharma is already manufacturing exhibit batches of the single dose Sputnik Light. While commercialization of other vaccines has reduced the opportunity to some extent in India, the same remains intact in other emerging countries.
Booster dose requirements are likely to make the vaccine an ongoing opportunity, rather than just a one-time affair. The contract is to supply to RDIF, and a diminishing India opportunity has a